{"id":26091,"date":"2021-09-03T17:20:14","date_gmt":"2021-09-03T15:20:14","guid":{"rendered":"https:\/\/www.transgene.com\/?p=26091"},"modified":"2025-12-09T14:42:43","modified_gmt":"2025-12-09T13:42:43","slug":"produits-bt-001-teaser","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/produits-bt-001-teaser\/","title":{"rendered":"produits : BT-001 teaser"},"content":{"rendered":"<div class=\"teaser\">\n<h4>BT-001 est un virus oncolytique arm\u00e9 exprimant un anticorps anti-CTLA4 et le GM-CSF, issu de la plateforme Invir.IO<sup>\u00ae<\/sup>.<\/h4>\n<p>Il a \u00e9t\u00e9 administr\u00e9 par voie intratumorale, dans une \u00e9tude de Phase 1\/2a multicentrique ouverte, \u00e9valuant des doses ascendantes de BT-001 seul et en combinaison avec pembrolizumab*.<\/p>\n<div class=\"breakSpace\">\n<p><span class=\"legende\"><em>*KEYTRUDA\u00ae est une marque d\u00e9pos\u00e9e de Merck Sharp &amp; Dohme LLC (MDS), filiale de Merck &amp; Co., Inc., Rahway, NJ, USA. <\/em><\/span><\/p>\n<p><a class=\"colorLien\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04725331\">Plus d&rsquo;information sur clinicaltrial.gov <\/a><\/p>\n<p>Une collaboration avec <img decoding=\"async\" class=\"logoCollabo\" src=\"..\/..\/wp-content\/uploads\/BioInvent-1.svg\" alt=\"BioInvent\" \/><\/p>\n<p>En savoir plus sur <a class=\"colorLien\" href=\"bt-001\/\">BT-001 <\/a><\/p>\n<p><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/615834632?width=640&amp;height=480\" rel=\"wp-video-lightbox\"> Mode d&rsquo;action de BT-001<\/a><\/p>\n<\/div>\n<\/div>\n\n\n<p class=\"eplus-wrapper wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BT-001 est un virus oncolytique arm\u00e9 exprimant un anticorps anti-CTLA4 et le GM-CSF, issu de la plateforme Invir.IO\u00ae. Il a \u00e9t\u00e9 administr\u00e9 par voie intratumorale, dans une \u00e9tude de Phase 1\/2a multicentrique ouverte, \u00e9valuant des doses ascendantes de BT-001 seul et en combinaison avec pembrolizumab*. *KEYTRUDA\u00ae est une marque d\u00e9pos\u00e9e de Merck Sharp &amp; Dohme&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/produits-bt-001-teaser\/\">Poursuivre la lecture <span class=\"screen-reader-text\">produits : BT-001 teaser<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[110],"tags":[],"class_list":["post-26091","post","type-post","status-publish","format-standard","hentry","category-outils-produits","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"BT-001 est un virus oncolytique arm\u00e9 exprimant un anticorps anti-CTLA4 et le GM-CSF, issu de la plateforme Invir.IO\u00ae. Il a \u00e9t\u00e9 administr\u00e9 par voie intratumorale, dans une \u00e9tude de Phase 1\/2a multicentrique ouverte, \u00e9valuant des doses ascendantes de BT-001 seul et en combinaison avec pembrolizumab*. *KEYTRUDA\u00ae est une marque d\u00e9pos\u00e9e de Merck Sharp &amp; Dohme&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=26091"}],"version-history":[{"count":10,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26091\/revisions"}],"predecessor-version":[{"id":39610,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26091\/revisions\/39610"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=26091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=26091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=26091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}